- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Transcript
What tools can physicians employ to improve adherence of hormonal therapies among patients with breast cancer?
I think, you know, a major tool that providers can do to help maintain patients on therapy is communication and listening to how patients are doing assessing their symptoms and acting, and if a patient needs to take a short break, if we need to rotate from one aromatase inhibitor to another, if we need to explore a supportive care medicine, or having a patient try acupuncture exercise—there's a lot of strategies to use.
But I think the most important thing is if a patient is unhappy or uncomfortable or feels like they, they just can't do it, we need to know, and we need to work on that together, rather than not hearing each other and then having somebody stop therapy early.
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
